Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Finlay A Macrae

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Journal of Gastroenterology and Hepatology|December 22, 2017
Predicting response after infliximab salvage in acute severe ulcerative colitisMatthew C Choy, Dean Seah, Alexandra Gorelik, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 8, 2018
Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in AustraliaJie-Bin Lew, D James B St John, Finlay A Macrae, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2006
Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family studyMark A Jenkins, Laura Baglietto, James G Dowty, et al.
International Journal of Cancer|February 15, 2018
Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in AustraliaJie-Bin Lew, D James B St John, Finlay A Macrae, et al.
Genes & Cancer|January 26, 2016
Genetic variants within the hTERT gene and the risk of colorectal cancer in Lynch syndromeAung Ko Win, Mark Clendenning, William Crawford, et al.
Human Mutation|December 2, 2010
Dependence of colorectal cancer risk on the parent-of-origin of mutations in DNA mismatch repair genesChristine M van Vliet, James G Dowty, Jane L van Vliet, et al.
International Journal of Cancer|October 18, 2002
After hMSH2 and hMLH1--what next? Analysis of three-generational, population-based, early-onset colorectal cancer familiesMark A Jenkins, Laura Baglietto, Gillian S Dite, et al.
The Medical Journal of Australia|October 10, 2019
The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndromeYoon-Jung Kang, James Killen, Michael Caruana, et al.
Familial Cancer|November 10, 2025
The germline POLD1 c.1420 C > A (p.Leu474Ile) variant segregates with endometrial cancer, colorectal cancer and colonic polyps demonstrating hypermutation and defective POLD1 mutational signaturesDaniel D Buchanan, Peter Georgeson, Romy Walker, et al.
The Medical Journal of Australia|September 11, 2009
Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications?Louise A Keogh, Christine M van Vliet, David M Studdert, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Journal of Gastroenterology and Hepatology|December 22, 2017
Predicting response after infliximab salvage in acute severe ulcerative colitisMatthew C Choy, Dean Seah, Alexandra Gorelik, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 8, 2018
Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in AustraliaJie-Bin Lew, D James B St John, Finlay A Macrae, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2006
Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family studyMark A Jenkins, Laura Baglietto, James G Dowty, et al.
International Journal of Cancer|February 15, 2018
Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in AustraliaJie-Bin Lew, D James B St John, Finlay A Macrae, et al.
Genes & Cancer|January 26, 2016
Genetic variants within the hTERT gene and the risk of colorectal cancer in Lynch syndromeAung Ko Win, Mark Clendenning, William Crawford, et al.
Human Mutation|December 2, 2010
Dependence of colorectal cancer risk on the parent-of-origin of mutations in DNA mismatch repair genesChristine M van Vliet, James G Dowty, Jane L van Vliet, et al.
International Journal of Cancer|October 18, 2002
After hMSH2 and hMLH1--what next? Analysis of three-generational, population-based, early-onset colorectal cancer familiesMark A Jenkins, Laura Baglietto, Gillian S Dite, et al.
The Medical Journal of Australia|October 10, 2019
The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndromeYoon-Jung Kang, James Killen, Michael Caruana, et al.
Familial Cancer|November 10, 2025
The germline POLD1 c.1420 C > A (p.Leu474Ile) variant segregates with endometrial cancer, colorectal cancer and colonic polyps demonstrating hypermutation and defective POLD1 mutational signaturesDaniel D Buchanan, Peter Georgeson, Romy Walker, et al.
The Medical Journal of Australia|September 11, 2009
Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications?Louise A Keogh, Christine M van Vliet, David M Studdert, et al.
Pageof 12